1. Moulder S, Hortobagyi GN. Advances in the treatment of breast cancer. Clin Pharmacol Ther. 2008; 83:26–36.
Article
2. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res. 2007; 5:195–201.
Article
3. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994; 73:2013–2026.
Article
4. Sinthupibulyakit C, Grimes KR, Domann FE, Xu Y, Fang F, Ittarat W, et al. p53 is an important factor for the radiosensitization effect of 2-deoxy-D-glucose. Int J Oncol. 2009; 35:609–615.
Article
5. Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci. 2000; 899:349–362.
Article
6. Kaabinejadian S, Fouladdel SH, Ramezani M, Azizi E. p53 expression in MCF7, T47D and MDA-MB 468 breast cancer cell lines treated with adriamycin using RT-PCR and immunocytochemistry. J Biol Sci. 2008; 8:380–385.
Article
7. Schwarz SB, Schaffer PM, Kulka U, Ertl-Wagner B, Hell R, Schaffer M. The effect of radio-adaptive doses on HT29 and GM637 cells. Radiat Oncol. 2008; 3:12.
Article
8. Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol. 2004; 52:103–116.
Article
9. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2005; 18:26–35.
Article
10. Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, Saceda M. Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol. 2004; 180:497–504.
Article
11. Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001; 1:233–240.
Article
12. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005; 102:13550–13555.
Article
13. Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, Karuppayil SM, et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem. 2006; 281:9837–9840.
Article
14. Carter SK. C.R.O.S. conference on combined modalities chemotherapy/radiotherapy. Hilton Head Island, South Carolina, November 15-18, 1978. Cancer Chemother Pharmacol. 1979; 2:139–142.
15. Tan ML, Choong PF, Dass CR. Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol. 2009; 61:131–142.
Article
16. O'Shaughnessy J. Liposomal anthracyclines for breast cancer: overview. Oncologist. 2003; 8:Suppl 2. 1–2.
17. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608:1–22.
Article
18. Bergh J, Jönsson PE, Glimelius B, Nygren P. SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 2001; 40:253–281.
19. Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997; 54:Suppl 4. 1–7.
20. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984; 226:466–468.
Article
21. Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med. 2005; 111:127–148.
Article
22. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic agents. In : Hardman JG, Lmbird LE, Gilman A, editors. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill;2001. p. 1389–1399.
23. Chanan-Khan A, Srinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol. 2004; 2:251–256.
24. Meek DW. The p53 response to DNA damage. DNA Repair (Amst). 2004; 3:1049–1056.
Article
25. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci. 2004; 95:7–11.
Article
26. Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 2005; 19:1162–1174.
Article
27. Ju GZ, Shen B, Sun SL, Yan FQ, Fu SB. Effect of X-rays on expression of caspase-3 and p53 in EL-4 cells and its biological implications. Biomed Environ Sci. 2007; 20:456–459.
28. Sasaki A, Udaka Y, Tsunoda Y, Yamamoto G, Tsuji M, Oyamada H, et al. Analysis of p53 and miRNA expression after irradiation of glioblastoma cell lines. Anticancer Res. 2012; 32:4709–4713.
29. Zhuang HQ, Wang J, Yuan ZY, Zhao LJ, Wang P, Wang CL. The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. J Exp Clin Cancer Res. 2009; 28:123.
Article